test

Solid Tumors

10
A Phase I Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Patients With Locally Advanced or Metastatic Solid Tumors And in Combination With Endocrine Therapy in Patients With Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Disease/Condition: Anus | Bladder | Breast - Female | Breast - Male | Cervix Uteri | Colon | Esophagus | Kidney | Larynx | Liver | Lung | Other Digestive Organ | Other Endocrine System | Other Female Genital | Other Male Genital | Other Respiratory and Intrathoracic Organs
Principal Investigator: Lajos Pusztai
A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4736 in Patients With Advanced Solid Tumors
Disease/Condition: Breast - Female | Colon | Esophagus | Kidney | Liver | Lung | Melanoma, skin | Pancreas
Principal Investigator: Joseph Paul Eder
A Phase I, Open-label, dose-escalation study of the safety and pharmacokinetics of MPDL3280A administered intravenously as a single agent to patients with locally advanced or metastatic solid tumors or hematologic malignancies
Disease/Condition: Bladder | Breast - Female | Colon | Esophagus | Kidney | Larynx | Lip, Oral Cavity and Pharynx | Lung | Melanoma, skin | Multiple Myeloma | Non-Hodgkin's Lymphoma | Other Digestive Organ | Other Male Genital | Pancreas | Prostate | Rectum | Soft Tissue | Stomach | Thyroid
Principal Investigator: Roy Herbst
A Phase I, Open-Label, Multiple Ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of MSB0010718C in Subjects with Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
Disease/Condition: Breast - Female | Colon | Lung | Melanoma, skin | Ovary | Rectum | Stomach
Principal Investigator: Joseph Paul Eder
A Phase I/II Study of the Combination of BKM120 and Bevacizumab, Glioblastoma Multiforme
Disease/Condition: Brain and Nervous System
Principal Investigator: Kevin Becker
A Phase Ib Multi-Cohort Study of MK-3475 in Subjects with Advanced Solid Tumors
Disease/Condition: Bladder | Breast - Female | Lip, Oral Cavity and Pharynx | Stomach
Principal Investigator: Lajos Pusztai
My Pathway: An Open Label Phase IIa Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib, and Vismodegib in Patients Who Have Advanced Cancer with Mutations or Gene Expression Abnormalities Predictive of Response to One of These Agents PRO-02
Disease/Condition: Bladder | Brain and Nervous System | Breast - Female | Colon | Esophagus | Lip, Oral Cavity and Pharynx | Liver | Lung | Melanoma, skin | Other Endocrine System | Ovary | Pancreas | Prostate | Rectum | Small Intestine | Soft Tissue | Stomach | Thyroid
Principal Investigator: Joseph Paul Eder
Novartis Signature - LGX818 for pts with BRAFV600 mutated tumors
Disease/Condition: Bladder | Brain and Nervous System | Breast - Female | Esophagus | Eye and Orbit | Kidney | Larynx | Lip, Oral Cavity and Pharynx | Liver | Lung | Melanoma, skin | Other Skin | Ovary | Pancreas | Prostate | Rectum | Small Intestine | Soft Tissue | Stomach
Principal Investigator: Joseph Paul Eder
Phase 2 Single Arm, Two Cohort Study Evaluating AMG 337 in Subjects with MET Amplif. GI/GEJ/E cancer
Disease/Condition: Esophagus | Stomach
Principal Investigator: Howard Hochster
Phase Ib Trial of MPDL3280A with Bevacizumab or with Bevacizumab + FOLFOX in Patients with Solid Tumors
Disease/Condition: Colon | Lung | Rectum
Principal Investigator: Howard Hochster